---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-028023"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:56:48.618354+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks

## Summary
- Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.
- OLE study shows continued weight loss up to 16.2% at 56 weeks; no plateau observed.
- Lower 2.5 mg starting dose improves tolerability; AE-related discontinuations 2-3.4% in interim OLE / body composition studies.
- End-of-Phase 2 meeting with FDA scheduled Q2 2026; Phase 3 initiation on track for 2H 2026.
- No drug-induced liver injury, no persistent liver enzyme elevations, no QTc prolongation across >625 participants.

## SEC filing metadata
- accession: 0001104659-26-028023
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/0001104659-26-028023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/tm268880d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-028023
- JSON: https://secwatch.observer/filing/0001104659-26-028023.json
- Plain text: https://secwatch.observer/filing/0001104659-26-028023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.